Psyence Group (TSE:PSYG) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Psyence Group has announced a deal to sell its 11.13% interest in PsyLabs to Psyence Biomed, which will bolster Psyence Biomed’s capabilities in developing psychedelic-based therapeutics. The agreement, valued at $1.1 million in common stock, is contingent on certain conditions including approvals and a product development milestone by PsyLabs.
For further insights into TSE:PSYG stock, check out TipRanks’ Stock Analysis page.